GlassScriptPhysician profile
Ashley Savage
NPI 1972111995
$8,872.22
in general payments reported to CMS, 2019-2025
17 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $2,428 · 2023: $1,951 · 2024: $2,112 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,912.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,444.49 | 2021-2025 | Precision 1, Tryptyr, Total30 |
| Coopervision INC. | $1,080.90 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $1,012.68 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $993.52 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $727.61 | 2022-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $631.61 | 2021-2025 | Cequa, Xelpros |
| Biotissue Holdings INC. | $548.99 | 2022-2025 | |
| Abbvie INC. | $460.48 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Sight Sciences, INC. | $409.19 | 2022-2023 | Tearcare System |
| Tarsus Pharmaceuticals, INC. | $347.44 | 2024-2025 | Xdemvy |
| Allergan, INC. | $324.34 | 2021-2022 | |
| Dompe US, INC. | $245.39 | 2022-2024 | Oxervate |
| Glaukos Corporation | $241.98 | 2023-2024 | Ce-Marked Kxla System |
| Eyevance Pharmaceuticals LLC | $162.63 | 2022 | |
| New World Medical,INC. | $127.52 | 2025 | Clearpath, Via360, Streamline |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $75.33 | 2023 | |
| Harrow Eye, LLC | $38.12 | 2024-2025 | Vevye, Natacyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.